Department of Neurosurgery, Affiliated HongQi Hospital of MuDanJiang Medical University, Mudanjiang City, China.
J Biol Regul Homeost Agents. 2018 May-Jun;32(3):731-736.
Glioma is the most common malignant tumor of the brain, which is difficult to be completely resected. The recurrence and mortality rates are high and the prognosis is poor. The aim of this study was to investigate the expression of anti-oncogene programmed cell death 4 (PDCD4) and programmed cell death 5 (PDCD5) in glioma and their influence on the progression of the disease in order to provide new therapeutic approaches. Reverse transcription polymerase chain reaction (RT-PCR) analysis was used to investigate PDCD4 mRNA and PDCD5 mRNA expression in 66 glioma patients who served as the study group and 22 patients who suffered from craniocerebral injuries or hematencephalon who were used as controls. The experimental group was divided into a low malignant group (tumors grade I - II) and a high malignant group (tumor grades III-IV). The PDCD4 mRNA and PDCD5 mRNA expression in the experimental group was 0.545±0.202 and 0.687±0.174 and in the control group was 0.942±0.131 and 0.868 ± 0.190, respectively (P less than 0.05). The PDCD4 mRNA and PDCD5 mRNA expressions in the low malignant group were 0.628±0.240 and 0.750±0.198, respectively, and in the high malignant group were 0.464±0.185 and 0.553±0.170, respectively (P less than 0.05). The results showed a downregulation of PDCD4 mRNA and PDCD5 mRNA expression in the experimental group compared with the control group. This downregulation was correlated with the pathological grade of glioma. In the high malignant group the PDCD4 mRNA and PDCD5 mRNA expressions were significantly decreased compared with the low malignant group and the control group. PDCD4 mRNA and PDCD5 mRNA expressions are promising targets for the diagnosis and treatment of glioma.
神经胶质瘤是最常见的脑恶性肿瘤，难以完全切除。复发率和死亡率高，预后差。本研究旨在探讨抑癌基因程序性细胞死亡因子 4（PDCD4）和程序性细胞死亡因子 5（PDCD5）在神经胶质瘤中的表达及其对疾病进展的影响，为神经胶质瘤的治疗提供新的方法。采用逆转录聚合酶链反应（RT-PCR）分析 66 例神经胶质瘤患者（研究组）和 22 例颅脑损伤或脑出血患者（对照组）的 PDCD4mRNA 和 PDCD5mRNA 表达。实验组分为低恶性组（肿瘤分级 I-II）和高恶性组（肿瘤分级 III-IV）。实验组 PDCD4mRNA 和 PDCD5mRNA 的表达分别为 0.545±0.202 和 0.687±0.174，对照组为 0.942±0.131 和 0.868±0.190，差异有统计学意义（P＜0.05）。低恶性组 PDCD4mRNA 和 PDCD5mRNA 的表达分别为 0.628±0.240 和 0.750±0.198，高恶性组分别为 0.464±0.185 和 0.553±0.170，差异有统计学意义（P＜0.05）。结果显示实验组 PDCD4mRNA 和 PDCD5mRNA 的表达较对照组下调，且与神经胶质瘤的病理分级有关。高恶性组 PDCD4mRNA 和 PDCD5mRNA 的表达明显低于低恶性组和对照组。PDCD4mRNA 和 PDCD5mRNA 的表达可能成为神经胶质瘤诊断和治疗的新靶点。
